Concepedia

Author

Alan B. Sandler

Vanderbilt University

Also Known As

A B Sandler, A. B. Sandler, A.B. Sandler, Alan B Sandler, Alan B. Sandler, Mary O'Brien, O'Brien, Mary E.R.

132

Publications

9.8K

Citations

49

H-Index

57

Concepts

All Affiliations

Vanderbilt UniversityDana-Farber Cancer InstituteVanderbilt-Ingram Cancer CenterThe University of Texas Southwestern Medical CenterIndiana University – Purdue University Indianapolis
AB

About

Alan B. Sandler is an author at Vanderbilt University specializing in oncology, medicine, and lung cancer.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

27

36

2.9K

2

Health Sciences

9

9

1.2K

3

Cell Biology

3

3

127

4

Public Health

1

1

29

5

Biochemistry

1

1

79

Alan B. Sandler

×

65

Publications

6.9K

Citations

40

H-Index

YearCitations

Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

Alan B. Sandler, John Nemunaitis, Claude Denham,

Journal of Clinical Oncology

2000

718

Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.

Michael B. Atkins, Michael J. Robertson, Michael S. Gordon,

PubMed

1997

590

Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599

Alan B. Sandler, R Gray, Julie R. Brahmer,

Journal of Clinical Oncology

2005

360

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

Suresh S. Ramalingam, Suzanne E. Dahlberg, Corey J. Langer,

Journal of Clinical Oncology

2007

350

Molecular Characteristics of Bronchioloalveolar Carcinoma and Adenocarcinoma, Bronchioloalveolar Carcinoma Subtype, Predict Response to Erlotinib

Vincent A. Miller, Gregory J. Riely, Maureen F. Zakowski,

Journal of Clinical Oncology

2008

299

Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study

Afshin Dowlati, Robert J. Gray, Alan B. Sandler,

Clinical Cancer Research

2008

260

Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594

Christopher J. Sweeney, Junming Zhu, Alan B. Sandler,

Cancer

2001

258

Clinical Course of Advanced Non–Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599

Suzanne E. Dahlberg, Alan B. Sandler, Julie R. Brahmer,

Journal of Clinical Oncology

2010

221

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

John V. Heymach, Luis Paz‐Ares, Filippo de Braud,

Journal of Clinical Oncology

2008

219

Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732

Harvey B. Niell, James E. Herndon, Antonius A. Miller,

Journal of Clinical Oncology

2005

187

Page 1